Global Life Technologies Corp. (GLT), the maker of Nozin Nasal Sanitizer antiseptic, shares that the Nozin MRSA Colonization Risk Mitigation Program was recently named one of The Leapfrog Group’s Best Infection Prevention Products for 2020. The Leapfrog Group worked with Newsweek to compile the list, evaluating products based on effectiveness, safety, successful real-world implementation and the stability of the company.
This Nozin infection prevention program has been shown to reduce MRSA (methicillin resistant Staphylococcus aureus) infection risks in hospitals and surgery centers by up to 81 percent. The Program utilizes Nozin Nasal Sanitizer antiseptic, which benefits patients and healthcare workers by reducing the levels of dangerous pathogens in the nose. Nasal colonization is the top risk factor for MRSA healthcare-associated infection (HAI).
Nozin Nasal Sanitizer employs a patented Nozaseptin formulation that delivers fast pathogen reduction and 12-hour persistence in a safe, pleasant application. The Nozin MRSA Colonization Risk Mitigation Program allows hospitals to reduce isolation of patients, decrease use of related PPE (personal protection equipment) by up to 40%, lower infection risks and improve utilization of staff time. In addition to providing experienced advisors, the Nozin Program offers proprietary analytical tools that help hospitals pinpoint needs and design customized solutions. An experienced Implementation team is also available to help with facility in-service and compliance.
“It is an honor to be selected by The Leapfrog Group and Newsweek for their Best Infection Prevention Products list,” said John Willimann, CEO of Global Life Technologies Corp. “We feel this is also recognition for the hundreds of hospitals that have adopted Nozin Programs and are reporting excellent outcomes. These facilities are achieving reduced infection risk, improved patient care, better staff time utilization and lower costs with Nozin as part of their innovative infection prevention programs.”
